Cue Biopharma, Inc. Additional Paid in Capital, Common Stock
Cue Biopharma, Inc. (CUE) had Additional Paid in Capital, Common Stock of $529.02 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $529.02M.
- 2026-03-31: Additional Paid in Capital, Common Stock $395.25M.
- 2025-12-31: Additional Paid in Capital, Common Stock $394.89M; Additional Paid in Capital, Common Stock as first filed $394.80M.
- 2025-09-30: Additional Paid in Capital, Common Stock $383.22M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $529.02M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $395.25M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $394.89M 10-Q · filed 2026-08-14 | $394.80M 10-K · filed 2026-03-16 |
| 2025-09-30 | $383.22M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $380.69M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $360.64M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $359.30M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $357.67M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $345.28M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $343.53M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $338.23M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $330.38M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $322.71M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $318.58M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $316.19M 10-K · filed 2024-03-28 | $316.19M 10-K · filed 2023-03-21 |
| 2022-09-30 | $286.69M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $284.63M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $276.34M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $262.91M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $252.55M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $248.95M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $235.43M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $232.16M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $229.63M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $212.12M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $166.28M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $163.07M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $126.58M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $112.85M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $107.79M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $105.76M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $99.58M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $96.84M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $95.57M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $94.41M 10-K · filed 2019-03-14 | $94.41M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |